Inhaled insulin, taken before meals, can improve blood glucose control for people with type 2 diabetes who have not had good results with short-acting injected insulin that is taken in addition to the baseline insulin administered throughout the day and night, according to a new review of the body of published research.
People who use insulin to manage their type 2 diabetes typically have to take extra insulin at mealtimes to regulate the glucose response to food. They can use short-acting injected insulin or inhaled insulin.
The review examined several clinical issues surrounding the use of inhaled insulin by patients with type 2 diabetes. It looked at how inhaled insulin compares to injected insulin as a mealtime insulin supplement for patients who are already using injected insulin daily.
The report also compared use of inhaled insulin by type 2 diabetes patients who had not previously taken insulin in any form. Inhaled insulin was compared to the effectiveness of oral antidiabetic drugs used alone and to antidiabetic drugs used with inhaled insulin.
In patients with type 2 diabetes, inhaled insulin worked as well as short-acting injected insulin to control blood glucose over three months, according to the review. However, inhaled insulin users had more trouble controlling low blood glucose — hypoglycemia —a common complication of diabetes medication.
“Insulin is associated with hypoglycemia,” said John Buse, M.D., president-elect of the American Diabetes Association. “That is its most common and potentially serious complication in all of its formulations.”
Among patients who had not previously taken insulin in any form, inhaled insulin alone was more effective than oral diabetes medication at controlling blood glucose levels at the three-month follow-up. When patients took oral medication plus inhaled insulin, higher rates of hypoglycemia occurred.
The Windows on Medical Technology report is published by ECRI Institute, an independent nonprofit health services research agency that researches the best approaches to improving patient care. The institute produces systematic reviews on medical devices, drugs, biotechnologies, procedures, and health services.
Jonathan Treadwell, Ph.D., senior research analyst at ECRI Institute, led a team of investigators who analyzed eight studies encompassing 1,881 patients with type 2 diabetes to make the comparisons between inhaled insulin, injected insulin, and oral medication regimens.
Despite some positive findings, the authors write, “the evidence regarding inhaled insulin for patients with type 2 diabetes is still insufficient to answer many key clinical questions” such as patient satisfaction, inhaled insulin's effect on other complications of diabetes, on weight gain, and very importantly, the long-term effects on lung function.
“One detail to note about inhaled insulin — the dosing is not as precise as with injections because specific increments in doses are not as precise,” Treadwell said. He added that companies who are developing inhaled insulin are working on more dose-tailored devices.
Type 2 diabetes occurs when glucose remains in the blood instead of being transported to cells as it is supposed to be. There is no cure, but the disorder can often be controlled with medication and lifestyle modifications. When these changes are insufficient to control diabetes, oral medication and sometimes insulin become necessary.
Insulin can be delivered through needle syringes, insulin pens, jet injectors and external infusion pumps. If uncontrolled, diabetes can lead to heart disease, blindness, kidney failure, nerve damage, poor circulation, amputation of limbs, and ultimately result in death.